

Please note: This document was created automatically and is not a substitute for the manufacturer's original document.

## Product Datasheet

### **Trastuzumab - Research Grade Biosimilar, CAS [[180288-69-1]], Unconjugated, Monoclonal PRS-21-854**

|                            |  |
|----------------------------|--|
| Article Name               | Trastuzumab - Research Grade Biosimilar, CAS [[180288-69-1]],<br>Unconjugated, Monoclonal  |
| Biozol Catalog Number      | PRS-21-854   |
| Supplier Catalog Number    | 21-854   |
| Alternative Catalog Number | PRS-21-854-0.1   |
| Manufacturer               | ProSci   |
| Category                   | Antikörper   |
| Immunogen                  | Humanized / ERBB2 (HER2, Tyrosine kinase-type cell surface receptor HER2, MLN19, Metastatic lymph node gene 19 protein, ERBB2, Proto-oncogene Neu, p185erbB2, CD_antigen=CD340, Proto-oncogene c-ErbB-2, MLN 19, NEU, Receptor tyrosine-protein kinase erbB-2, |
| Conjugation                | Unconjugated   |
| Clonality                  | Monoclonal   |
| Concentration              | batch dependent  |
| NCBI                       | <a href="#">2064</a>   |
| UniProt                    | <a href="#">P04626</a>   |
| Buffer                     | PBS buffer pH 7.5  |
| Source                     | CHO cells  |
| Purity                     | >95%   |

|                    |   |
|--------------------|---|
| CAS Number         | [180288-69-1]   |
| Application Dilute | For research use only .   |
| Application Notes  | Treatment of HER2-overexpressing breast cancer cell lines with Trastuzumab results in induction of p27KIP1 and the Rb-related protein, p130, which in turn significantly reduces the number of cells undergoing S-phase. A number of other phenotypic changes |